Drug Trial Radar · NCT01657162
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Dec 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,139
Actual
Start
Nov 20, 2012
Primary completion
Oct 3, 2016
Study completion Oct 3, 2016
Sponsor
- Lead sponsor
- Radius Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
Conditions
- Postmenopausal Osteoporosis
Interventions
AlendronateDrug
Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With ≥1 New Vertebral Fracture Since Study BA058-05-003 BaselineTime frame: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)
Locations
25 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Lakewood, Colorado
Site not named
Hialeah, Florida
Site not named
Bethesda, Maryland
Site not named
Buenos Aires, Argentina
Site not named
Brasília, Brazil
Site not named
Curitiba, Brazil
Site not named
Rio de Janeiro, Brazil
Site not named
São Paulo, Brazil
Site not named
Vitória, Brazil
Site not named
Brno, Czechia
Site not named
Brno-Vinohrady, Czechia
Site not named
Pardubice, Czechia
Site not named
Aalborg, Denmark
Site not named
Ballerup Municipality, Denmark
Site not named
Vejle, Denmark
Site not named
Tallinn, Estonia
Site not named
Tartu, Estonia
Site not named
Hong Kong, Hong Kong
Site not named
Vilnius, Lithuania
Site not named
Bialystok, Poland
Site not named
Kielce, Poland
Site not named
Lodz, Poland
Site not named
Warsaw, Poland
Site not named
Zgierz, Poland
Site not named
Bucharest, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.